Akari Therapeutics, PLC

75/76 Wimpole Street

London W1G 9RT

United Kingdom

 

November 7, 2022

 

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

 

Re:	Akari Therapeutics, PLC
	Registration Statement on Form F-1 File No. 333-267840

VIA EDGAR

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, PLC (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-267840) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on November 8, 2022 or as soon thereafter as may be practicable.

 

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP, by calling Richard Bass at (212) 547-5476. The Company hereby authorizes Mr. Bass to orally modify or withdraw this request for acceleration.

 

‘

 

 

 

	Very truly yours,
	AKARI THERAPEUTICS, PLC
	By:	/s/ Torsten Hombeck
	Name: Torsten Hombeck
	Title: Chief Financial Officer